{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:44:36Z","timestamp":1793411076338,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"\n Importance<\/jats:title>\n Menopause is defined as the cessation of a person\u2019s menstrual cycle. It is defined retrospectively, 12 months after the final menstrual period. Perimenopause, or the menopausal transition, is the few-year time period preceding a person\u2019s final menstrual period and is characterized by increasing menstrual cycle length variability and periods of amenorrhea, and often symptoms such as vasomotor dysfunction. The prevalence and incidence of most chronic diseases (eg, cardiovascular disease, cancer, osteoporosis, and fracture) increase with age, and US persons who reach menopause are expected on average to live more than another 30 years.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal persons and whether outcomes vary by age or by timing of intervention after menopause.<\/jats:p>\n <\/jats:sec>\n \n Population<\/jats:title>\n Asymptomatic postmenopausal persons who are considering hormone therapy for the primary prevention of chronic medical conditions.<\/jats:p>\n <\/jats:sec>\n \n Evidence Assessment<\/jats:title>\n The USPSTF concludes with moderate certainty that the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons with an intact uterus has no net benefit. The USPSTF concludes with moderate certainty that the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy has no net benefit.<\/jats:p>\n <\/jats:sec>\n \n Recommendation<\/jats:title>\n The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons. (D recommendation) The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy. (D recommendation)<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2022.18625","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T11:09:11Z","timestamp":1667300951000},"page":"1740","source":"Crossref","is-referenced-by-count":105,"title":["Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons"],"prefix":"10.1001","volume":"328","author":[{"name":"US Preventive Services Task Force","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M.","family":"Mangione","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Barry","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda K.","family":"Nicholson","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cabana","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Caughey","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chelmow","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tumaini Rucker","family":"Coker","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa M.","family":"Davis","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina E.","family":"Donahue","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Roberto","family":"Ja\u00e9n","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center, San Antonio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Kubik","sequence":"additional","affiliation":[{"name":"George Mason University, Fairfax, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"University of Virginia, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gbenga","family":"Ogedegbe","sequence":"additional","affiliation":[{"name":"New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Pbert","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School, Worcester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"University of Arizona, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stevermer","sequence":"additional","affiliation":[{"name":"University of Missouri, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Wong","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"jus220027r1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-7-200904070-01004","article-title":"In the clinic: menopause.","volume":"150","author":"Col","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"jus220027r2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/gme.0b013e31824d8f40","article-title":"Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.","volume":"19","author":"Harlow","year":"2012","journal-title":"Menopause"},{"issue":"2","key":"jus220027r3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0378-5122(95)00985-X","article-title":"The normal menopause transition: an overview.","volume":"23","author":"McKinlay","year":"1996","journal-title":"Maturitas"},{"issue":"13","key":"jus220027r7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials.","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"jus220027r9","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.18324","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US Preventive Services Task Force.","author":"Gartlehner","year":"2022","journal-title":"JAMA"},{"issue":"16","key":"jus220027r10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement.","volume":"327","author":"US Preventive Services Task Force","year":"2022","journal-title":"JAMA"},{"issue":"16","key":"jus220027r11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1001\/jama.2021.4987","article-title":"Screening for hypertension in adults: US Preventive Services Task Force reaffirmation recommendation statement.","volume":"325","author":"US Preventive Services Task Force","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"jus220027r12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jama.2021.12531","article-title":"Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement.","volume":"326","author":"US Preventive Services Task Force","year":"2021","journal-title":"JAMA"},{"issue":"20","key":"jus220027r13","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1001\/jama.2020.21749","article-title":"Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force recommendation statement.","volume":"324","author":"US Preventive Services Task Force","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"jus220027r14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jama.2017.7171","article-title":"Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without cardiovascular risk factors: US Preventive Services Task Force recommendation statement.","volume":"318","author":"US Preventive Services Task Force","year":"2017","journal-title":"JAMA"},{"issue":"24","key":"jus220027r15","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement.","volume":"319","author":"US Preventive Services Task Force","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"jus220027r16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/M15-2886","article-title":"Screening for breast cancer: US Preventive Services Task Force recommendation statement.","volume":"164","author":"Siu","year":"2016","journal-title":"Ann Intern Med"},{"issue":"19","key":"jus220027r17","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2021.6238","article-title":"Screening for colorectal cancer: US Preventive Services Task Force recommendation statement.","volume":"325","author":"US Preventive Services Task Force","year":"2021","journal-title":"JAMA"},{"issue":"22","key":"jus220027r18","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1001\/jama.2017.18261","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement.","volume":"318","author":"US Preventive Services Task Force","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"jus220027r19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women\u2019s Health Initiative randomized clinical trials.","volume":"324","author":"Chlebowski","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"jus220027r20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/aje\/kwaa033","article-title":"Dual-outcome intention-to-treat analyses in the Women\u2019s Health Initiative randomized controlled hormone therapy trials.","volume":"189","author":"Prentice","year":"2020","journal-title":"Am J Epidemiol"},{"issue":"13","key":"jus220027r21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2011.382","article-title":"Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.","volume":"305","author":"LaCroix","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"jus220027r22","first-page":"302","article-title":"No increase in fractures after stopping hormone therapy: results from the Women\u2019s Health Initiative.","volume":"102","author":"Watts","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"jus220027r23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1056\/NEJM200008243430801","article-title":"Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.","volume":"343","author":"Herrington","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"jus220027r24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","article-title":"Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s Health Initiative Hormone Trial.","volume":"47","author":"Margolis","year":"2004","journal-title":"Diabetologia"},{"issue":"1","key":"jus220027r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-138-1-200301070-00005","article-title":"Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen\/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial.","volume":"138","author":"Kanaya","year":"2003","journal-title":"Ann Intern Med"},{"issue":"13","key":"jus220027r26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis.","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"jus220027r27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.maturitas.2006.01.012","article-title":"Results from the Estonian postmenopausal hormone therapy trial.","volume":"55","author":"Veerus","year":"2006","journal-title":"Maturitas"},{"issue":"20","key":"jus220027r28","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","article-title":"Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women\u2019s Health Initiative Memory Study: a randomized controlled trial.","volume":"289","author":"Shumaker","year":"2003","journal-title":"JAMA"},{"issue":"24","key":"jus220027r29","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","article-title":"Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women\u2019s Health Initiative Memory Study.","volume":"291","author":"Shumaker","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"jus220027r30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","article-title":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial.","volume":"273","author":"Writing Group for the PEPI Trial","year":"1995","journal-title":"JAMA"},{"issue":"5, pt 1","key":"jus220027r31","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/01.AOG.0000180394.08406.15","article-title":"Postmenopausal hormone therapy: does it cause incontinence?","volume":"106","author":"Steinauer","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"1","key":"jus220027r32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/aje\/kwp115","article-title":"Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.","volume":"170","author":"Prentice","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"6","key":"jus220027r33","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/01.AOG.0000431053.33593.2d","article-title":"ACOG Committee Opinion No. 565: hormone therapy and heart disease.","volume":"121","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"4","key":"jus220027r34","first-page":"269","article-title":"ACOG releases practice bulletin on osteoporosis.","volume":"88","author":"Hauk","year":"2013","journal-title":"Am Fam Physician"},{"issue":"10","key":"jus220027r35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/GME.0000000000000319","article-title":"The North American Menopause Society recommendations for clinical care of midlife women.","volume":"21","author":"Shifren","year":"2014","journal-title":"Menopause"},{"key":"jus220027r8","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.18324","volume-title":"Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: An Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 222","author":"Gartlehner","year":"2022"},{"key":"jus220027r4","unstructured":"Social Security Administration. Actuarial life table: period life table, 2010. Accessed September 2, 2022. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"jus220027r5","unstructured":"US Preventive Services Task Force. US Preventive Services Task Force Procedure Manual. Published May 2021. Accessed September 2, 2022. https:\/\/uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual"},{"key":"jus220027r6","unstructured":"Pfizer Inc. Premarin prescribing information. Accessed September 2, 2022. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=131"},{"key":"jus220027r36","unstructured":"American Academy of Family Physicians. Clinical Preventive Service Recommendation: hormone replacement therapy. Accessed September 2, 2022. https:\/\/www.aafp.org\/family-physician\/patient-care\/clinical-recommendations\/all-clinical-recommendations\/hrt.html"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2797867\/jama_mangione_2022_us_220027_1666287322.83064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T17:25:55Z","timestamp":1678469155000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2797867"}},"subtitle":["US Preventive Services Task Force Recommendation Statement"],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":36,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.18625","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}